Skip to main content

Lunate Capital Ltd

13F filer · CIK 0002056786
Reported Jul 23, 2026
Net buyer this quarter
13F portfolio value$196MU.S. long equity reported on 13F
Positions106 new · 2 closed
Net flow last quarter+$14.3MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Jul 23, 202610 positions
SAILSailPoint, Inc.$43.9M22.41%0.53%Not reportedQ1 2025
BIRKBirkenstock Holding plc$43.5M22.17%0.54%NewQ2 2026
LINELineage, Inc.$26M13.24%0.26%Not reportedQ1 2025
BXSLBlackstone Secured Lending Fund$23.7M12.11%0.43%NewQ2 2026
GSBDGoldman Sachs BDC, Inc.$20.8M10.60%1.95%NewQ2 2026
MSDLMorgan Stanley Direct Lending Fund$16.7M8.51%1.31%NewQ2 2026
OBDCBlue Owl Capital Corp$13M6.66%0.24%NewQ2 2026
NAVNNavan, Inc.$4.57M2.33%0.44%Not reportedQ4 2025
NMRANeumora Therapeutics, Inc.$3.61M1.84%1.15%Not reportedQ1 2025
FIGFigma, Inc.$240K0.12%Not reportedNewQ2 2026
Q1 2026Reported Apr 16, 20266 positions
RVMDRevolution Medicines, Inc.$53.4M44.36%0.27%-75.0%Q1 2025
SAILSailPoint, Inc.$39.7M33.00%0.53%Not reportedQ1 2025
LINELineage, Inc.$19.7M16.33%0.26%Not reportedQ1 2025
NMRANeumora Therapeutics, Inc.$4.14M3.44%1.17%Not reportedQ1 2025
NAVNNavan, Inc.$2.65M2.20%0.44%Not reportedQ4 2025
RVMDWRevolution Medicines, Inc.$806K0.67%Not reportedNot reportedQ2 2025
Q4 2025Reported Jan 23, 20266 positions
RVMDRevolution Medicines, Inc.$175M66.20%1.11%Not reportedQ1 2025
SAILSailPoint, Inc.$60.7M22.97%0.53%Not reportedQ1 2025
LINELineage, Inc.$21M7.95%0.26%Not reportedQ1 2025
NMRANeumora Therapeutics, Inc.$3.8M1.44%1.22%Not reportedQ1 2025
NAVNNavan, Inc.$3.42M1.29%0.44%NewQ4 2025
RVMDWRevolution Medicines, Inc.$423K0.16%Not reportedNot reportedQ2 2025
Q3 2025Reported Nov 20, 20256 positions
RVMDRevolution Medicines, Inc.$103M46.47%1.16%Not reportedQ1 2025
SAILSailPoint, Inc.$66.2M30.01%0.54%Not reportedQ1 2025
FIGRFigure Technology Solutions, Inc.$24.7M11.21%Not reportedNewQ3 2025
LINELineage, Inc.$23.2M10.50%0.26%Not reportedQ1 2025
NMRANeumora Therapeutics, Inc.$3.87M1.75%1.31%Not reportedQ1 2025
RVMDWRevolution Medicines, Inc.$135K0.06%Not reportedNot reportedQ2 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.